CharlesLanceCoweyMD

Oncology • Dallas, TX

Genitourinary Oncology, Hematologic Oncology, Melanoma

Texas Oncology, PA/Medical Oncologist

Join to view full profile

Dr. Cowey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cowey's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1202
Is this information wrong?

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Alabama Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Texas Medical Branch School of MedicineClass of 2003

Certifications & Licensure

TX State Medical License 2009 - 2024
NC State Medical License 2006 - 2009
AL State Medical License Active through 2006

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2019 Dec 12
Completed
Phase 1, Phase 2
Roles: Principal Investigator
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

15 citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance Fernandez, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna ...> ;Clinical Cancer Research. 2023 Sep 1
12 citations
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
James Larkin, Jeffrey Weber, Michele Del Vecchio, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni,...> ;European Journal of Cancer. 2022 Sep 1
34 citations
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhi...
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Márquez-Rodas, Anna Spreafico, Victoria Atkinson, Fe...> ;Journal of Clinical Oncology. 2023 Jan 1
Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma.
Thao T Vo, Janet L Espirito, Marley Boyd, Burak Gumuscu, Diana Chirovsky, Nicholas J Robert, Ramona F Swaby, Wei Zhou, Charles Lance Cowey> ;Future Oncology. 2022 Jun 1
324 citations
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
, , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2021 Nov 24
3 citations
Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Abhijeet Bhanegaonkar, Frank X Liu, Marley Boyd, Nicole Fulcher, Ruth Kim, Stan Krulewicz, Jodi Smith, C. Lance Cowey> ;The Oncologist. 2021 Sep 1
8 citations
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandalà, James E. Larkin, Paolo A. Ascierto, Michele Del Vecchio, Helen Gogas, C. Lance Cowey, Ana Arance, Stéphane Dalle, Michael Schenker, Jean-Jacques Grob, V...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
4 citations
Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
Patricia LoRusso, Aleksandar Sekulic, Jeffrey A. Sosman, Winnie S. Liang, John D. Carpten, David Craig, David B. Solit, Alan H. Bryce, Jeff Kiefer, Jessica Aldrich, Sa...> ;Plos One. 2021 Apr 7
2 citations
Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
Charles Lance Cowey, Emilie Scherrer, Marley Boyd, Kathleen M. Aguilar, April Beeks, Clemens Krepler> ;Journal of Immunotherapy. 2021 Mar 17
9 citations
Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Charles Lance Cowey, Frank X Liu, Ruth Kim, Marley Boyd, Nicole Fulcher, Stan Krulewicz, Vijay Kasturi, Abhijeet Bhanegaonkar> ;Future Oncology. 2021 Mar 12
271 citations
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, contr...
Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sil...> ;The Lancet. Oncology. 2020 Nov 1
3 citations
An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 ...
Charles Lance Cowey, Marley Boyd, Kathleen M. Aguilar, April Beeks, Clemens Krepler, Emilie Scherrer> ;Cancer Medicine. 2020 Sep 1
33 citations
Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy
C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer Frytak, Israel Lowy, Matthew G. Fury> ;Cancer Medicine. 2020 Jun 24
38 citations
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
Omid Hamid, C. Lance Cowey, Mark B. Faries, Richard D. Carvajal> ;Cancers. 2019 Oct 24
24 citations
Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant a...
C. Lance Cowey, Frank Xiaoqing Liu, Marley Boyd, Kathleen M. Aguilar, Clemens Krepler> ;Medicine. 2019 Jul 1
39 citations
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante, Jason J. Luke, Jose Lutzky, Neal Evan Rothschild, Lynn E. Spitler, C. Lance Co...> ;Cancer. 2019 Apr 1
878 citations
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
, , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2018 Nov 1
27 citations
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
C. Lance Cowey, Frank Xiaoqing Liu, Jenny Black-Shinn, Kendall Lee Stevinson, Marley Boyd, Jennifer Frytak, Scot Ebbinghaus> ;Journal of Immunotherapy. 2017 Dec 1
15 citations
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sigrun Hallmeyer, Rene Gonzalez, David H. Lawson, Lee D. Cranmer, Gerald P. Linette, Igor Puzanov, Bret Taback, C. Lance Cowey, Antoni Ribas, Gregory A. Daniels, Timot...> ;Melanoma Research. 2017 Dec 1
12 citations
Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Raghad M Abdul-Karim, C. Lance Cowey> ;Cancer Management and Research. 2017 Sep 25
1425 citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Ro...> ;The New England Journal of Medicine. 2017 Sep 10
64 citations
Health-related quality of life results from the phase III CheckMate 067 study
, , , , , , , , , , , , , , , , , , , , , > ;European Journal of Cancer. 2017 Sep 1
302 citations
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis o...
, , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2017 Aug 25
83 citations
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
C. Lance Cowey, Lisa Mahnke, Janet Espirito, Christoph Helwig, D. Oksen, Murtuza Bharmal> ;Future Oncology. 2017 Jun 13
17 citations
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
Lijo John, C. Lance Cowey> ;Dermatology and Therapy. 2015 Sep 19
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Baylor University Medical CenterDallas, Texas
Medical City DallasDallas, Texas
Baylor Scott & White Institute for Rehabilitation - DallasDallas, Texas